期刊
CHEMMEDCHEM
卷 10, 期 11, 页码 1863-1874出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201500334
关键词
6-methyluracil; acetylcholinesterase; Alzheimer's disease; molecular modeling; reversible inhibitors
资金
- Russian Science Foundation (RSF) [14-50-00014]
- Russian Foundation for Basic Research (RFBR) [13-00-40286-K]
- Dynasty Foundation (Russia)
- Russian Science Foundation [14-50-00014] Funding Source: Russian Science Foundation
Novel 6-methyluracil derivatives with -(substituted benzylethylamino)alkyl chains at the nitrogen atoms of the pyrimidine ring were designed and synthesized. The numbers of methylene groups in the alkyl chains were varied along with the electron-withdrawing substituents on the benzyl rings. The compounds are mixed-type reversible inhibitors of cholinesterases, and some of them show remarkable selectivity for human acetylcholinesterase (hAChE), with inhibitory potency in the nanomolar range, more than 10000-fold higher than that for human butyrylcholinesterase (hBuChE). Molecular modeling studies indicate that these compounds are bifunctional AChE inhibitors, spanning the enzyme active site gorge and binding to its peripheral anionic site (PAS). In vivo experiments show that the 6-methyluracil derivatives are able to penetrate the blood-brain barrier (BBB), inhibiting brain-tissue AChE. The most potent AChE inhibitor, 3d (1,3-bis[5-(o-nitrobenzylethylamino)pentyl]-6-methyluracil), was found to improve working memory in scopolamine and transgenic APP/PS1 murine models of Alzheimer's disease, and to significantly decrease the number and area of -amyloid peptide plaques in the brain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据